Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ALLK.................................https://stockcharts.com/h-sc/ui?s=ALLK&p=W&b=5&g=0&id=p86431144783
nice set up
ALLK..........................................................................https://stockcharts.com/h-sc/ui?s=ALLK&p=W&b=5&g=0&id=p86431144783
THIS POS IS A SCAM GONNA GO DOWN DOWN DOWN!!!
imo
We will go short on this one.
Agree, the next couple weeks should be very interesting .
The whole Nasdaq is crashing. A stock whose IP doesn’t work should be pulverized next week.
Made it go down 95%. The technology doesn’t work….
It was a good flip, still looks attractive at this level, but I will wait .
This aged well
Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported data from ENIGMA 2, a 24-week Phase 3 randomized, double-blind, placebo-controlled study of lirentelimab in patients with biopsy confirmed eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) and KRYPTOS, a 24-week Phase 2/3 randomized, double-blind, placebo-controlled study of lirentelimab in patients with biopsy-confirmed eosinophilic esophagitis (EoE). Both ENIGMA 2 and KRYPTOS studies met their histologic co-primary endpoints, but did not achieve statistical significance on the patient reported symptomatic co-primary endpoints.
“We are deeply disappointed that the studies did not achieve their symptomatic endpoints,” said Robert Alexander, PhD, Chief Executive Officer of Allakos. “The company is grateful to the patients with eosinophilic gastrointestinal diseases (EGIDs) and to the investigators who participated in the ENIGMA and KRYPTOS trials.”
Zero squeeeze. What’s up with this company. How’d it lose 97% of value in one year?
So what’s the deal with this stock? Why has the stock price fallen 97%? Where do you see the company has $500m cash on hand?
Yup, total scam, run away.
Allakos holders - please read and share the link below.
Stock wash sale 30 days period ended on 21 January 2022. December sellers will be looking to buy back now. Two after hours buys yesterday make more sense now.
ALLK is a forgotten share, but not for those who have to buy it back. The seller is gone for two days, but the sentiment is negative around all Nasdaq shares hence negative ends on Thu and Fr. This will change too.
I saw on Thursday 20 January that there was an appetite to climb up, really. Virtually no seller around. During the day all was going well, MMs were ticking it nicely higher until that moment of crash caused by Netflix followed by the entire Nasdaq falling down. Friday Nasdaq still down so ALLK too. But every crash ends and reversal starts for new buyers.
Look, as ALLK holders, we all can and have to create a need for shorters and those who sold in December for tax reasons to start the buy back. We need an bigger action to close day at 5-10% up to get noticed in media.
I. e. ADGI reversed exactly after 30 days wash sale. Allakos can do the same if we really want it.
Sell only if you really have to or Hold it for a few more days to see if recovery kicks in with Nasdaq stabilising.
Allakos Inc at $7 mcap is slightly lower than cash and equivalents.
We know they did not deliver but ffs share is down from $84 to $7 and they still be looking to use thst drug in another areas.
Please share the below post on Twitter for awareness.
https://twitter.com/inves2day/status/1485023226753437698?t=aK2TQngCviUwopFKMOEmjQ&s=19
Thank you for reading and sharing.
*23 Jan - my account on StockTwits has been suspended after posting the above link*
well this has 3 stages for me, everything +9.50, allright
everything above 10+, superb
everything above 12.50, winner winner chicken dinner.
A company with 500 million up their sleeves, I think they might figure something out.
And whats more, why did I buy into this company?
I have EOE myself, it's being triggered by cow milk with me and my throat and stumach gets hurt really bad by the eosiphiniles If I don't watch out with avoiding everything with milk.
I'm totally wondered here how that however the drug significantly reducing the eosiphiniles in situ doesn't get a response on the symptons, this starts me wondering if the direct symptons only thrive by the (food)allergy people have with it.
For now, I avoid milk and use omeprazole to completly suppres the effects, corticosteriod can be used locally but they are bad for blood vessels long term.
To get to the point, I think this drug isn't wrote off at all, the eosiphiniles do damage the throat a lot long term in this disease, if left untreathed, the throat will start forming circular scars, making it smaller and making it long term impossible to get food into the stumach.
The research completly ignores this problem, while it's the second main cause for treating this disease, unimaginable if you ask me.
Two Stocks to Watch: #NXTD ?? #ALLK ?? Should you buy now for the possible run-up? Technical analysis!
DD here Can someone Box/Sticky it
https://twitter.com/tryingBot05/status/1473861479309152257
https://twitter.com/RealTimeTradez/status/1473987872197914633/photo/1
https://twitter.com/SilentTrader93/status/1474112595133177859
https://twitter.com/RealTimeTradez/status/1473809286354583557
https://twitter.com/RealTimeTradez/status/1474081174448398343
ALLK New Patient Dec.21 2021
https://twitter.com/RealTimeTradez/status/1473987872197914633/photo/1
that's what i'm here scouting out. looks like analysts have different opinions on price. from 10.00 to 60.00
i think it is a short attack and whatever else
Agree, a little bit more Consolidations, before the next leg up, then BOOOOM .
looks like the Short Squeeze commencing!
Very small SS short squeeze will take it to the moon .
I’m good with $50 lol .
Maybe they'll buy their own stock. LOL.
And GOLDMAN lowered the price target to $60.00...(6X) from here. Some see things others don't.
9.91 > Morgan Stanley Maintains Equal-Weight on Allakos, Lowers Price Target to $10
All these analysts are comedians!
Expecting $15-$20 next week .